Ian Setliff
@IanSetliff
Followers
374
Following
348
Media
1
Statuses
251
Antibodies, Immunology, Protein Engineering, Comp Bio. @urichmond, @VanderbiltU and @Regeneron alum. Views mine.
Anywhere
Joined July 2015
TRAPnSeq allows high-throughput profiling of antigen-specific antibody-secreting cells
cell.com
Asrat et al. develop a method, TRAPnSeq, that enables specific isolation and profiling of antigen-specific (Ag+) antibody-secreting cells. They show the utility of TRAPnSeq in mice and humans by...
0
1
1
High-throughput discovery of #epitope-specific #antibodies? There's a #LIBRAseq for that. Great collaborative effort led by @LaurenW_Science. High-Throughput B Cell Epitope Determination by Next-Generation Sequencing
frontiersin.org
Development of novel technologies for the discovery of human monoclonal antibodies has proven invaluable in the fight against infectious diseases. Among the ...
1
8
27
#LIBRAseq with ligand blocking enables targeted discovery of functional (not just binding) #antibodies. Double #ACE2-blockers for both #SARSCoV2 and #SARSCoV were also identified. Easily generalizable for #mAb discovery aiming to block other types of antigen-ligand interactions
Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking https://t.co/hWNXnppf33
3
16
48
Great place to do science!
We have a postdoctoral opening in antibody discovery, with a special emphasis on the development and application of innovative #bioinformatics technologies. Come do cutting-edge research in #antibody and #vaccine science in #Nashville, one of the hottest destinations in the US!
1
1
6
Out now in @CellReports: Potent neutralization of #SARSCoV2 variants of concern (including #Delta) by an #antibody with an uncommon genetic signature and structural mode of spike recognition
0
0
4
Out now in @CellReports: Potent neutralization of #SARSCoV2 variants of concern (including #Delta) by an #antibody with an uncommon genetic signature and structural mode of spike recognition
cell.com
Kramer et al. demonstrate that antibody 54042-4 recognizes residues highly conserved across global SARS-CoV-2 isolates. Antibody 54042-4 potently neutralizes all known circulating variants of concern...
2
28
80
Announcing our Phase 3 trial in advanced #CervicalCancer was stopped early after achieving its primary efficacy endpoint. Today’s milestone is a “first” for the cervical cancer community. Learn why: https://t.co/ePL40tmYfR CC: @Sanofi
1
6
30
Today, the FDA accepted for review our sBLA for a treatment for children aged 6 to 11 years with moderate-to-severe #asthma. Learn more: https://t.co/9udThffNN0
@sanofi
0
5
21
We announced new data on our investigational medicine for patients with #cat allergy and mild asthma at #AAAAI21. Learn more: https://t.co/vKZlP3MqWo
0
6
24
With @Sanofi, we are announcing the FDA approval of our #immunotherapy in first-line advanced #NonSmallCellLungCancer (#NSCLC) with ≥50% PD-L1 expression. Learn more: https://t.co/A5PzpTqoz0
1
12
44
Today the FDA approved a first-of-its-kind treatment for people with #HoFH, an ultra #rare inherited form of high cholesterol. Read the full announcement: https://t.co/C7ojzpAH8v
0
5
30
Announcing with @Sanofi, the FDA has granted full approval to our #immunotherapy for patients with locally advanced #BasalCell Carcinoma (#BCC) and accelerated approval for patients with metastatic #BCC. Learn more: https://t.co/Zu8cicfaad
3
9
38
Great place to do science!
Pursue your passion for #science in a dynamic and innovative environment. Apply by December 1 to be a part of the Regeneron Postdoctoral Program.
0
0
2
The FDA has issued an Emergency Use Authorization for our investigational antibody cocktail to treat mild to moderate #COVID19 in certain high-risk patients 12 years and older. Learn more: https://t.co/yNfOFPyLI0
24
124
288
Announcing positive data from 524 additional non-hospitalized #COVID19 patients in ongoing P2/3 study of Regeneron’s investigational antibody cocktail: https://t.co/FOVKNlZRn0
9
90
192
#Breaking: The FDA has approved our novel anti-viral #antibody medicine for Zaire ebolavirus in adult and pediatric patients. #Ebola Read the full announcement: https://t.co/a8S7QhXMBw
3
32
107
#SoundOn 📣. It’s impossible to be still, especially when we have the power to transform lives. See how we go from #SciencetoMedicine.
23
30
69